LOUISVILLE, CO, September 11, 2024 – AmideBio, LLC, a privately-held biopharmaceutical company, announced today that it has received $1.93M in funding through a Direct-to-Phase 2 Small Business Innovation Research (SBIR) …
AmideBio Awarded SBIR Phase IIB Grant to Support Pre-Clinical Development of its Long- Acting Stable Glucagon Analog for the Treatment of Hyperinsulinism
BOULDER, CO, October 4th, 2022 – AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $2.69M in funding through a Phase IIB Small Business Innovation Research …